The Relationship Between Serum Levels Of CA- 125 and Interleukin -6 with the Degree of Differentiation in Ovarian Neoplasms
DOI:
https://doi.org/10.21276/apalm.2549Keywords:
Ovarian neoplasm, CA-125, Interleukin-6Abstract
Background: To study the serological correlation between serum levels of CA -125 and IL-6 with various histo morphological features of ovarian neoplasm.
Methods: Prospective study of two year duration from 2016 to 2018.Total of 40 women presented clinically with pelvic mass lesion were included. These patients undergoing concomitant serological analysis of CA -125 and IL-6. In each case, age, parity, marital life, radiological finding, histological type, degree of differentiation, extra ovarian tissues involvement was determined.
Result: Most of the ovarian neoplasm belongs to benign category 19/40 (47.5%) then malignant tumors 15/40 (37.5%). Surface epithelial tumours (80%) were common histopathological findings with raised CA-125 and Interleukin-6 levels. Most of the patient present with abdominal pain in their late reproductive age group (41-60 years). There is significant correlation ( p-value=.000) in rise of levels of CA-125 and Interleukin-6 levels in patients with benign and malignant ovarian lesion. Levels of both the biomarkers are near normal levels in benign cases and levels were raised in malignant cases.
Conclusion: Amongst the ovarian neoplasm benign tumor were more common than malignant with predominance histological type is surface epithelial tumors. Serum levels of CA —125 and IL-6 were associated with histological grade in primary ovarian neoplasms, especially in high-grade malignant tumors, suggesting that high serological levels of these biomarkers are associated with lesions of more aggressive biological behavior.
References
2. Adelmen S, Benson CD, Hertzler JH, surgical lesion of the ovary in infancy & childhood, surggynecolobstate 1975, 141 : 219-222
3. Gupta N, Bisht D, Agrawal AK, Sharma UK, Comoarative study of ovarian cyst and tumour, J Pak Medical association December 2000,50(12);416-419.
4. Scully RE, Clement PB, Young RH, Miscellaneous primary tumours, secondary tumours, and non-neoplastic lesions of ovary. In : Mills SE, Carter D, Greenson JK, Oberman HA, Renter V, Stoler MH edts. Sternberg's diagnostic surgical pathology, 4th edn. Philadelphia : Lippincott Williams and Wilkins; 2004.p.2617
5. Zurawski VR, Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42:677—680. [PubMed]
6. Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, et al.Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res.1993;207(2):332—9. doi:10.1006/excr.1993.1200.
7. Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol.1993;49(1):8—15. doi:10.1006/gyno.1993.1077.
8. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 transsignaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71(2):424—34. doi:10.1158/0008-5472.can-10-1496.
9. Friedman, EL, Hayes, DF, Kufe, DW. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. 1986;46:5189—5194.
10. Bast, RC Jr, Knauf, S, Epenetos, A et al, Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Hybridoma. 1987;6:228.
11. Gruhn JG. A selected historical survey pathology emphasizing neoplasms. In: Roth LM, Czernobilsky B (eds). Tumours and Tumour-like Conditions of the Ovary (Chapter 13). Churchill Livingstone: New York, 1985.
12. Graham H. Eternal Eve. The History of Gynaecology and Obstetrics. Doubleday and Company, Inc.: New York, 1951.
13. Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumours: a study of 282 cases. J Indian Med Assoc 2002; 100: 420, 423-4, 447.Morgagni GB. The Seats and Causes of Diseases (English Translation by Benjamin Alexander). Miller A, Cadell T and Johnson and Payne: London, 1769.
14. Ahmad Z, Kayani N, Hasan SH, Muzaffar S, Gill MS. Histological pattern of ovarian neoplasm. J Pak Med Assoc 2000; 50: 416-9.
15. Oumachigui, Narasimhan KL, Reddy KS, et al. A clinicopathologic study of ovarian tumours in children. J Obstet Gynecol. 1991;140:441—5.
16. Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumours: a study of 282 cases. J Indian Med Assoc 2002; 100: 420, 423-4, 447.
17. 17. Ahmad Z, Kayani N, Hasan SH, Muzaffar S, Gill MS. Histological pattern of ovarian neoplasm. J Pak Med Assoc 2000; 50: 416-9.
18. Rathi V et al Study Of Histopathological Spectrum Of Ovarian Lesions, Vikram University,Ujjain,2005.
19. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a10 year review. Obstet Gynaecol 1989; 74: 921-26
20. Rafiq B, Kokab H, Rao SI. Ovarian tumours. Professional Med J 2005;12(4):397—403.
21. R Jha& S Karki , Nepal Medical College,Journal 2008:109(2)81-85.
22. Levi1 F, Vecchia CL, Randimbison L, Te VC. Borderline ovarian tumours in Vaud. Switzerland: incidence, survival and second neoplasms. Br J Cancer 1999;79(1):4—6
23. Burkholz KJ, Wood BP, Zuppan C. Best Cases from the AFIP: Borderline papillary serous tumour of the right ovary. Radiographics 2005;25:1689—92.
24. Outwater EK, Siegelman ES, Kim B, Chiowanich P, Blasbalg R, Kilger A. Ovarian Brenner tumours: MR imaging characteristics. Magn Reson Imaging 1998;16:1147—53
25. Herbst AL. The Epidemiology of Ovarian Carcinoma and the Current Status of Tumour Markers to Detect Disease. Am JObstet Gynecol 1994;170:1099—107.
26. Di Bonito L, Patriarca S, Delendi M, Alberico S. Ovarian tumours: anatomohistopathological contribution to their interpretation. Eur J Gynaecol Oncol 1988; 9: 324-30.
27. Chakrabortti DK, Lee CMS. Epidemiological study ovarian neoplasms. J Obstet gynaecol India 1990; 40:582 -6.
28. Greggi S, Parazzini F, Paratore MP, Chatenoud L, Legge F, Mancuso S et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol 2000; 79:50-4.
29. Salazar-Martinez E, Lazeano-Pance EC, Gonzalez Lira-Lira G, Escudero- De Los Rios P, Salmeron-Castro J, Hernandez-Avila M. Cancer Res 1999; 59:3658-62.
30. Yen ML, Yen BL, Bai CH, Lin RS. Risk factors for ovarian cancer in Taiwan: a case control study in a low incidence population. Gynecol Oncol 2003; 89: 318-24.
31. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol 2004; 92: 320-6
32. KOLWIJICK, E. et al. Preoperative CA-125 level in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer, v. 19, n. 8, p. 1335-8, 2009.
33. OSMAN, N. et al. Correlation of serum CA125 levels with stage, grade and survival of patients with epithelial ovarian cancer. J Clin Oncol, v. 25, n.18, suppl. 16006, 2007.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Minakshi Rajput, C. V. Kulkarni, Ashok Yadav, Sachin Sharma, Vinod Dhakad
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
